Diagnostic transcript and splice patterns of HPV16 in different cervical lesions

Patent metadata

Field	Value
Publication number	US-9803253-B2
Application number	US-200913128201-A
Country	US
Kind code	B2
Filing date	Nov 9, 2009
Priority date	Nov 7, 2008
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

A method is described for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of the first gene product and the amount of the second gene product. A composition is also described, including an oligonucleotide mixture, and also a kit and a device adapted to carry out the described method.

First claim

The invention claimed is:

1. A method for differentiating in a human subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection, said human subject not comprising the HPV16 genome in an integrated form, and for treating said human subject having said severe form infection comprising the steps of:
a) determining, in a sample of said human subject, the presence or absence of a gene product of 880^2582, said sample selected form the group consisting of a scrape, a biopsy, or a wash/rinse fluid from urogenital tract, a cervical smear, and a Pap smear,
and
b) differentiating between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on the determination performed in step a), wherein the presence of the gene product of 880^2582 indicates the severe form of HPV16 infection, and wherein the absence of the gene product of 880^2582 indicates a mild form of HPV16 infection,
wherein the determination of the presence or absence of the gene product comprises the steps of amplifying the gene product with primer oligonucleotides that specifically amplify the gene product and determining the presence or absence of the amplified gene product, wherein the amplification step comprises generation of a cDNA, wherein the determining step is performed by a probe oligonucleotide having a nucleic acid sequence that comprises SEQ ID NO: 4, and
c) treating said human subject having said severe form infection comprising a treatment step selected from the group consisting of conisation, loop electrosurgical excision procedure (LEEP), trachelectomy, hysterectomy, chemotherapy, and radiochemotherapy.

2. The method of claim 1 , wherein the gene product of 880^2582 are spliced transcripts comprising the 880^2582 junction.

3. The method of claim 1 , wherein the probe oligonucleotide has a nucleic acid sequence that comprises SEQ ID NO: 63.

4. A method for differentiating in a human subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection, and for treating said human subject having said severe form infection comprising the steps of:
a) determining, in a sample of said human subject, the presence or absence of a gene product of 880^2582, said sample selected form the group consisting of a scrape, a biopsy, or a wash/rinse fluid from urogenital tract, a cervical smear, and a Pap smear,
b) assessing in the sample of said human subject the integration status of the HPV16 genome and
c) differentiating between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on the determination performed in step a), wherein the presence of the gene product of 880^2582 indicates the severe form of HPV16 infection, and wherein the absence of the gene product of 880^2582 indicates a mild form of HPV16 infection,
wherein the determination of the presence or absence of the gene product comprises the steps of amplifying the gene product with primer oligonucleotides primers that specifically amplify the gene product and determining the presence or absence of the amplified gene product, wherein the amplification step comprises generation of a cDNA, wherein the determining step is performed by a probe oligonucleotide having a nucleic acid sequence that comprises SEQ ID NO: 4, and
treating said human subject having said severe form infection comprising a treatment step selected from the group consisting of conisation, loop electrosurgical excision procedure (LEEP), trachelectomy, hysterectomy, chemotherapy, and radiochemotherapy.

5. A method for differentiating in a human subject with HPV16, between (i) a low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), or cervix carcinoma and (ii) a negative for intraepithelial lesions or malignancy (NIL/M), said human subject not comprising the HPV16 genome in an integrated form, and for treating said human subject in category (i) comprising the steps of:
a) determining, in a sample of said human subject, the presence or absence of a gene product of 880^2582, said sample selected form the group consisting of a scrape, a biopsy, or a wash/rinse fluid from urogenital tract, a cervical smear, and a Pap smear,
and
b) differentiating between (i) a LSIL, HSIL, or cervix carcinoma and (ii) a NIL/M based on the determination performed in step a), wherein the presence of the gene product of 880^2582 indicates the severe form of HPV16 infection, and wherein the absence of the gene product of 880^2582 indicates a mild form of HPV16 infection,
wherein the determination of the presence or absence of the gene product comprises the steps of amplifying the gene product with primer oligonucleotides that specifically amplify the gene product and determining the presence or absence of the amplified gene product, wherein the amplification step comprises generation of a cDNA, wherein the determining step is performed by a probe oligonucleotide having a nucleic acid sequence that comprises SEQ ID NO: 4, and
treating said human subject in category (i) comprising a treatment step selected from the group consisting of conisation, loop electrosurgical excision procedure (LEEP), trachelectomy, hysterectomy, chemotherapy, and radiochemotherapy.

6. A method for diagnosing in a human subject with HPV16 a severe form of HPV16 infection, said human subject not comprising the HPV16 genome in an integrated form, and for treating said human subject having said severe form infection comprising the steps of:
a) determining, in a sample of said human subject, the presence or absence of a gene product of 880^2582, said sample selected form the group consisting of a scrape, a biopsy, or a wash/rinse fluid from urogenital tract, a cervical smear, and a Pap smear,
and
b) diagnosing a severe form of HPV16 infection based on the determination performed in step a), wherein the presence of the gene product of 880^2582 indicates the severe form of HPV16 infection, and wherein the absence of the gene product of 880^2582 indicates a mild form of HPV16 infection,
wherein the determination of the presence or absence of the gene product comprises the steps of amplifying the gene product with primer oligonucleotides that specifically amplify the gene product and determining the presence or absence of the amplified gene product, wherein the amplification step comprises generation of a cDNA, wherein the determining step is performed by a probe oligonucleotide having a nucleic acid sequence that comprises SEQ ID NO: 4, and
treating said human subject having said severe form infection comprising a treatment step selected from the group consisting of conisation, loop electrosurgical excision procedure (LEEP), trachelectomy, hysterectomy, chemotherapy, and radiochemotherapy.

Assignees

• Schmitt Markus
• Gissmann Lutz
• Pawlita Michael
• Deutsches Krebsforsch

Inventors

• Schmitt Markus
• Gissmann Lutz
• Pawlita Michael

Classifications

• C12Q1/708 Primary

  for papilloma · CPC title

• C12Q2545/113

  with an external standard/control, i.e. control reaction is separated from the test/target reaction · CPC title